Licensing and Collaborations
Dyadic is interested in strategic partnerships with industry leaders in various sectors including animal health and nutrition, biofuels, chemicals and fibers, food products, diagnostics, health and beauty aids, and pharmaceuticals.
Dyadic works with its partners to discover new biomaterials, develop new products, lower costs and reduce waste, improve yields, enhance the quality of end products, enhance the intellectual property position of its partners’ gene discoveries and products, and manufacture biological products.
The business relationship with Dyadic can cover all aspects of the process from gene and protein discovery to commercial scale manufacturing for a partner, or just a specific portion of the R&D and commercialization process.
Dyadic is very flexible in structuring its collaborations to suit the needs of its partner which may include the following:
– Funded R&D with an accompanying license for commercial rights to resulting products (with or without Dyadic manufacturing products for the partner)
– Joint ventures in defined fields for discovering, developing, manufacturing and commercializing products emanating from the application of Dyadic’s genomics technology
Dyadic is developing functional biomolecule libraries for other companies to access – under suitable business arrangements – to screen for products of commercial value. When desired by a business partner, Dyadic will screen soil samples and other sources for novel eukaryotic genes and proteins of commercial value.
Dyadic is also interested in collaboration with independent researchers, as well as scientists at research institutions, universities and commercial establishments where a research partnership is of mutual benefit.
If you are interested in Dyadic’s manufacturing capabilities for your biological products, please visit the Manufacturing section of our site.
The following is a list of some of Dyadic’s most important collaborations:
|Company||Year begun||Rights to C1||Fields (end markets)|
2009 (License) 2012 (Expanded License)
|Non-exclusive rights to improve, modify and use C1 in the licensed fields||Enzymatic hydrolysis of biomass substrates in biorefining processes (e.g., using C1 to create sugar primarily for use in biofuels, bio-based chemicals and power production)|
|2013||Non-exclusive rights to improve, modify and use C1 in the licensed fields||Multiple Markets|
|2008||Non-exclusive rights to improve, modify and use C1 in the licensed fields||– Biofuels (limited to Shell as Codexis’ exclusive partner)
— Pharmaceutical intermediates
— Bio-based chemicals
— Air treatment
|2011||Non-exclusive R&D collaboration and exclusive license option to use C1 to produce developed vaccines||Biopharmaceuticals (specific types of vaccines)|
|Major animal health & nutrition company||2011||Non-exclusive research collaboration and rights to use customized C1 strain in licensed field||Animal health and nutrition (production of a specific product line)|
|Market leading food and enzyme company||2012||Non-exclusive research collaboration and rights to use customized C1 strain in licensed field||Food (production of a specific enzyme)|
|Leading animal health & nutrition company||2012||Non-exclusive research collaboration and rights to use customized C1 strain in licensed field||Animal health and nutrition (production of a specific enzyme)|